Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour Application - Full Text View

Sponsor:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00466570

Purpose

Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

Condition	Intervention
Conjunctical Flora	Drug: gatifloxacin, moxifloxacin

Study Type:	Interventional
Study Design:	Prevention, Randomized, Single Blind, Active Control, Factorial Assignment, Efficacy Study
Official Title:	Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics

Drug Information available for: Gatifloxacin Moxifloxacin Moxifloxacin hydrochloride

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

Antibiotic killing of conjunctival bacterial flora 1 hour after application

Estimated Enrollment:	100
Study Start Date:	April 2007

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age- older than 50 years of age
Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

Systemic or topical antibiotic treatment within 30 days
Use of systemic or topical steroids
Active ocular infection
Ocular surgery in the past 6 months
Allergy to fluoroquinolones

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00466570

Contacts

Contact: Miri Englander, BA

650 804 8408

MiriMD@Stanford.edu

Locations

United States, California
Stanford University	Recruiting
Stanford, California, United States, 94305
Contact: Christopher Ta, MD 650-723-6995 cta@stanford.edu
Contact: Miri Englander, BA 650 804 8408
Principal Investigator: Christopher Ta, MD

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Christopher Ta, MD

Stanford University

More Information

Publications:

Ta CN, He L, Nguyen E, De Kaspar HM. Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. Eur J Ophthalmol. 2006 May-Jun;16(3):359-64.

Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005 Apr;139(4):730-3.

de Kaspar HM, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004 Dec;13(6):507-9.

Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, Mino de Kaspar H. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003 Oct;110(10):1946-51.

Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Mino De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002 Nov;109(11):2036-40; discussion 2040-1.

Study ID Numbers:	8924
Study First Received:	April 25, 2007
Last Updated:	April 26, 2007
ClinicalTrials.gov Identifier:	NCT00466570 History of Changes
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Anti-Infective Agents
Moxifloxacin
Therapeutic Uses
Pharmacologic Actions
Gatifloxacin

ClinicalTrials.gov processed this record on November 09, 2009